U.S. Congress legislation · 119th Congress
HB9559: IBOGAINE Act
Status: In committee, July 17, 2026
To accelerate the development of, and access to, psychedelic drugs that could save lives and reverse the crisis of serious mental illness in the United States, and for other purposes.
What the bill says
To accelerate the development of, and access to, psychedelic drugs that could save lives and reverse the crisis of serious mental illness in the United States, and for other purposes.
From the introduced text, June 30, 2026:
A BILL To accelerate the development of, and access to, psychedelic drugs that could save lives and reverse the crisis of serious mental illness in the United States, and for other purposes. SECTION 1. Short title This Act may be cited as the Initiating Biomedical Outcomes to Garner Advancements into Innovative Neuroplastogen Efficacy Act or the IBOGAINE Act . SECTION 2. Table of contents The table of contents of this Act is as follows: Sec. 1. Short title. Sec. 2. Table of contents. Sec. 3. Definitions. Sec. 4. National Health Priority Voucher Pilot Program. Sec. 5. Amendment to the Federal right to try law. Sec. 6. Special registration requirements related to right to try. Sec. 7. Revising considerations for DEA quota requirements. Sec. 8. Federal-State collaboration. Sec. 9. Interagency collaboration with the private sector. Sec. 10. Timely rescheduling. Sec. 11. Designation of senior official for emerging therapeutic interventions within the Department of Veterans Affairs. Sec. 12. Emerging therapeutic interventions at the Department of Veterans Affairs. Sec. 13. Report on accelerating medical treatments for serious mental illness. SECTION 3. Definitions Section 102 of the Controlled Substances Act ( 21 U.S.C. 802 ) is amended by adding at the end the following: (61) The term ibogaine means-- (A) all parts of the plant Tabernanthe iboga; and (B) any similar compound or analog …
Sponsors
- Morgan Luttrell (R, HD-008) · primary sponsor
- Michael McCaul (R, HD-010)
- Jack Bergman (R, HD-001)
- Luis Correa (D, HD-CA-46)
- Mike Collins (R, HD-010)
- Sarah Elfreth (D, HD-003)
Latest actions
- : Referred to the Subcommittee on Health.
- : Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- : Introduced in House
Subjects: Health
Common questions
- What is HB9559?
- HB9559 is a bill in Congress (119th Congress): IBOGAINE Act.
- What does HB9559 do?
- In its own words: To accelerate the development of, and access to, psychedelic drugs that could save lives and reverse the crisis of serious mental illness in the United States, and for other purposes.
- What is the status of HB9559?
- In committee as of July 17, 2026. Latest action: Referred to the Subcommittee on Health. (July 17, 2026).
- Who sponsored HB9559?
- Morgan Luttrell (R, HD-008), with 5 co-sponsors.
- Where is the official record for HB9559?
- On the Congress website: https://www.congress.gov/bill/119th-congress/house-bill/9559
Source: official Congress record. Tracked by Delilah, AI for legislation across all 50 states and Congress.